Lexicon Pharmaceuticals, Inc. (LXRX)

1,6000 -0,0100 (-0,62%) Börsenschluss: 04:00PM EDT

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000
https://www.lexpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 285

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Lonnel Coats	CEO & Director	1,14M	N/A	1965
Mr. Jeffrey L. Wade J.D.	President & CFO	752,05k	N/A	1965
Mr. Brian T. Crum	Senior VP, General Counsel & Secretary	596,48k	N/A	1973
Dr. Alan J. Main Ph.D.	Executive Vice President of Innovation & Chemical Sciences	576,96k	N/A	1954
Dr. Craig B. Granowitz M.D., Ph.D.	Senior VP & Chief Medical Officer	652,48k	N/A	1965
Ms. Kristen L. Alexander	Vice President of Finance & Accounting	N/A	N/A	1968
Ms. Lisa M. DeFrancesco	Head of Investor Relations & Corporate Strategy	N/A	N/A	1980
Mr. Dixon Terry	Vice President of Compliance	N/A	N/A	N/A
Ms. Carrie Siragusa	Vice President of Marketing	N/A	N/A	N/A
Ms. Desiree Gendron	Vice President of Sales & Training	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 8, Vorstand: 10, Shareholderrechte: 7, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.